FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Udai Banerji

Research Profile

Disorders

Chemicals & Drugs

Procedures

Activities & Behaviors

Clinical Trials, Phase I as Topic

Concepts & Ideas

Co-author Network

Publications

TOP 3
David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
V Moreno Garcia; M Puglisi; Keerti V Shah; Parames Thavasu; J Vitfell Pedersen; B Basu; M Blanco Codesido; Johann S de Bono; J Iqbal; S B Kaye; L R Molife; Udai Banerji
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.
Joo Ern Ang; Stan Kaye; Udai Banerji
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Udai Banerji (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: David S Hong; Joann Aaron; Udai Banerji; Goldy C George; Bahareh Tavana; Razelle Kurzrock
Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Cancer treatment reviews 2013;39(4):375-87.
2012: V Moreno Garcia; M Puglisi; Keerti V Shah; Parames Thavasu; J Vitfell Pedersen; B Basu; M Blanco Codesido; Johann S de Bono; J Iqbal; S B Kaye; L R Molife; Udai Banerji
Association of creatine kinase and skin toxicity in phase I trials of anticancer agents.
British journal of cancer 2012;107(11):1797-800.
2012: Joo Ern Ang; Stan Kaye; Udai Banerji
Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
Current drug targets 2012;13(12):1525-34.
2012: Aung Naing; E Oelmann; DAVID oLMOS; E Raymond; G Schwartz; R Taylor; W Burke; L Grinsted; S Kaye; R Kurzrock; C Aghajanian; Udai Banerji
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.
British journal of cancer 2012;107(7):1093-9.
2012: Maria Martinez-Garcia; Valerie Meresse Naegelen; Federico Rojo; Emilie Routier; Ruediger Rueger; Eliezer Shochat; Joan Albanell; Rastilav Bahleda; Udai Banerji; Steve Blotner; Saoirse Dolly; Ernesto Guarin; Françoise Kraeber-Bodéré; Jean J L Tessier; Zhi-Xin Xu; Jean-Charles Soria
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(17):4806-19.
2012: L R Molife; DAVID oLMOS; M Puglisi; K Shah; A Tjokrowidjaja; L Trani; S Alam; Udai Banerji; Johann S de Bono; R Fehrmann; S B Kaye
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(8):1968-73.
2012: Bissan Al-Lazikani; Udai Banerji; Paul Workman
Combinatorial drug therapy for cancer in the post-genomic era.
Nature biotechnology 2012;30(7):679-92.
2012: Craig P Carden; Paul A Clarke; Mateus Crespo; Johann S de Bono; Michelle D Garrett; Martin Gore; Stan B Kaye; Emma Kipps; Susana Miranda; Lorna Pope; Adam Stewart; Parames Thavasu; Paul Workman; Gerhardt Attard; Udai Banerji
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Molecular cancer therapeutics 2012;11(7):1609-17.
2012: Udai Banerji; Johann S de Bono; Phillip Debnam; Michelle D Garrett; Leon Hooftman; Rebecca Kristeleit; Dionysis Papadatos-Pastos; Florence Raynaud; Adam Stewart; Matthew Tall; Martin Toal; Leni van Doorn; Jaap Verweij; Ferry A L M Eskens
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(9):2687-94.
2012: Christophe Massard; L Rhoda Molife; Dionysis Papadatos-Pastos; Shahneen Sandhu; Franck Saran; Jean-Charles Soria; Montserrat Blanco; Craig Carden; Johann De Bono; Stan B Kaye; Udai Banerji
Toward a better dialogue between neuro-oncologists and phase I investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):562-3; author reply 563-4.
2012: Geraldine Perkins; Lorna Pope; Ruth Riisnaes; Khin Thway; Timothy A Yap; Gerhardt Attard; Udai Banerji; Amy M Cassidy; Philippe A Cassier; Jeremy Clark; Katie A Denholm; Juliet P Dukes; David Gonzalez De Castro; Stan B Kaye; Christophe Massard; Susana Miranda; L Rhoda Molife; Johann S de Bono
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.
PloS one 2012;7(11):e47020.
2012: B Basu; Johann S de Bono; S B Kaye; S Malvankar; L R Molife; V Moreno Garcia; M Puglisi; K Shah; A Tjokrowidjaja; J Vitfell-Pedersen; B Anghan; Udai Banerji
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials.
Oncology 2012;83(4):177-82.
2012: Loreta M Rodrigues; Swee Y Sharp; Marion Stubbs; Nada M S Al Saffar; Udai Banerji; Yuen-Li Chung; John R Griffiths; Laura E Jackson; Martin O Leach; Paul Workman
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
BMC research notes 2012;5():250.
2011: Dionysis Papadatos-Pastos; Udai Banerji
Revisiting the role of molecular targeted therapies in patients with brain metastases.
Journal of neuro-oncology 2011;105(3):467-74.
2011: Montserrat Blanco Codesido; Sophia Frentzas; L Rhoda Molife; Victor Moreno Garcia; Dionysis Papadatos-Pastos; Joanna Vitfell Pedersen; Martina Puglisi; Andre Tesainer Brunetto; Leonardo Trani; Udai Banerji
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.
Oncology 2011;81(2):135-40.
2010: Andre T Brunetto; Joo Ern Ang; DAVID oLMOS; Daniel Tan; Jorge Barriuso; Hendrik-Tobias Arkenau; Timothy A Yap; L Rhoda Molife; Udai Banerji; Johann S de Bono; Ian Judson; Stan Kaye
A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.
European journal of cancer (Oxford, England : 1990) 2010;46(15):2739-45.
2009: Daniel S W Tan; George V Thomas; Michelle D Garrett; Udai Banerji; Johann S de Bono; Stan B Kaye; Paul Workman
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Cancer journal (Sudbury, Mass.) 2009;15(5):406-20.
2009: S Postel-Vinay; Hendrik-Tobias Arkenau; DAVID oLMOS; J Ang; J Barriuso; Sue Ashley; Udai Banerji; Johann S de Bono; Ian Judson; Stan Kaye
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
British journal of cancer 2009;100(9):1373-8.
2009: C P Carden; Udai Banerji; S B Kaye; Paul Workman; J S de Bono
From darkness to light with biomarkers in early clinical trials of cancer drugs.
Clinical pharmacology and therapeutics 2009;85(2):131-3.
2008: Udai Banerji; Nivedita Sain; Swee Y Sharp; Melanie Valenti; Yasmin Asad; Ruth Ruddle; Florence I Raynaud; Michael Walton; Suzanne A Eccles; Ian Judson; Ann L Jackman; Paul Workman
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Cancer chemotherapy and pharmacology 2008;62(5):769-78.
2008: Udai Banerji; Annette Affolter; Ian Judson; Richard Marais; Paul Workman
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.
Molecular cancer therapeutics 2008;7(4):737-9.
2007: Alison Maloney; Paul A Clarke; Soren Naaby-Hansen; Rob Stein; Jens Koopm,ann; Akunna Akpan; Alice Yang; Marketa Zvelebil; Rainer Cramer; Lindsay Stimson; Wynne Aherne; Udai Banerji; Ian Judson; Swee Sharp; Marissa Powers; Emmanuel deBilly; Joanne Salmons; Michael Walton; Al L Burlingame; Michael D Waterfield; Paul Workman
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Cancer research 2007;67(7):3239-53.
2006: Simon Pacey; Udai Banerji; Ian Judson; Paul Workman
Hsp90 inhibitors in the clinic.
Handbook of experimental pharmacology 2006;(172):331-58.
2005: Udai Banerji; Michael Walton; Florence I Raynaud; Rachel Grimshaw; Lloyd R Kelland; Melanie Valenti; Ian Judson; Paul Workman
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):7023-32.
2005: Udai Banerji; Anne O'Donnell; Michelle Scurr; Simon Pacey; Sarah Stapleton; Yasmin Asad; Laura Simmons; Alison Maloney; Florence I Raynaud; Maeli Campbell; Michael Walton; Sunil Lakhani; Stan Kaye; Paul Workman; Ian Judson
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4152-61.
2003: Udai Banerji; Ian Judson; Paul Workman
The clinical applications of heat shock protein inhibitors in cancer - present and future.
Current cancer drug targets 2003;3(5):385-90.
2000: Paul A Clarke; I Hostein; Udai Banerji; F D Stefano; Alison Maloney; Michael Walton; Ian Judson; Paul Workman
Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
Oncogene 2000;19(36):4125-33.